Clinical Trial Update: Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED) [Phase 1]

View source ↗

Summary

A completed Phase 1 safety study of ridaforolimus (MK-8669) in patients with advanced, refractory or recurrent malignancies, including lymphoma and multiple mye…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Multiple Myeloma
• Solid Tumors

Drugs mentioned

• Ridaforolimus (ridaforolimus)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Tumors, Lymphoma | Phase 1 | Status: COMPLETED